A survey of GLP-1 users reveals how appetite suppression reshapes pleasure, social life, daily routines, finances, and long-term fears in ways the scale alone can’t capture.

Weight loss has long been talked about in terms of pounds lost. For millions of Americans using GLP-1 medications, the change isn’t just physical. Nearly 12% of U.S. adults say they’ve taken a GLP-1 drug like Ozempic®, Wegovy®, or Mounjaro®, marking a rise in the popularity of these medications. GLP-1s are rapidly moving beyond niche medical use into mainstream health conversations, transforming how people eat, socialize, work, spend, and even see themselves.

As GLP-1s shift from celebrity headlines into everyday life, the effects extend well past the scale. To better understand what life on these medications really feels like, Shed surveyed 1,000 U.S. adults who have taken GLP-1s to capture a fuller picture of their lived experience. The data reveal complex trade-offs—confidence and control on one hand, and challenges around pleasure, privacy, and physical comfort on the other. What follows is a closer look at how these drugs are reshaping modern life.

Key takeaways

• Over half of GLP-1 users say it has improved their social experiences, including 63% who enjoy exercise more, 60% who enjoy travel more, and 58% who enjoy family gatherings more.
• 71% feel more control over their food, with 20% being more intentional about their diet, and 24% finding food less tempting or appealing.
• While 49% are saving money on their grocery bill, 26% are spending more on higher-quality food, and 22% end up buying too much food or wasting it due to appetite changes.
• 70% feel food is more enjoyable after starting GLP-1s, and 31% fear weight gain if they stop taking them, rising to 45% among Boomers and 37% among women.
• 75% experience digestive side effects from GLP-1s on a monthly basis, and 54% on a daily or weekly basis.
• 20% report sleep disruption due to GLP-1 side effects, and 28% say fatigue affects their ability to work.
• 56% feel more supported when they tell loved ones about their GLP-1 use, while 21% stay private and only share with their healthcare providers. 

A new relationship with weight—and with life

Taking GLP-1s can change more than just the way you look; it can also change how you feel about yourself. A significant shift in confidence causes a shift in behavior, too. With a new outlook after weight loss, events that used to be stressful become a lot more fun.

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Over half (57%) said they enjoyed holidays and celebrations more after starting their medication and a similar amount (58%) said that family gatherings were more enjoyable. After all, it’s easier to get through Christmas if your nosy aunt isn't commenting on your portion sizes during dinner.

This new attitude extends outside special occasions: 63% say taking GLP-1s made their workouts more enjoyable. Taking GLP-1s helps these patients to view exercise as an act of self-care instead of a high-pressure habit they must uphold. Losing weight can also relieve pressure on the joints, making exercise easier and less potentially painful. Three in five patients (60%) enjoy traveling and vacations more than before GLP-1s. When you feel more confident in your bathing suit, tropical vacations are a breeze.  

Feeling confident in public often makes people feel more confident at home, too. Over two in five (41%) users say that their clothes fit better after weight loss, while 37% say their old clothes don’t fit as well, but the change is still positive. That new confidence carries over when the clothes come off, too. A third (31%) of users say that intimacy was better after starting GLP-1s, and another 23% said their partner felt more attraction to them after weight loss. 

However, the confidence of respondents became mixed when it came to dining out and going to bars. While 48% say they enjoy going out to eat more after GLP-1s, 23% enjoy it less. Nearly one in five (17%) says they have difficulty enjoying food-related activities overall. Even so, this can help break bad habits for many GLP-1 users. Almost a third (27%) report that they drink or use recreational substances less often after starting their medication. For many users, less pull toward food and drinking helps support better habits overall.

Eating with intention: How GLP-1s change your relationship with food

Because GLP-1 usage necessarily requires a high amount of control over your diet, some users find their attitudes toward food change. For those who tend to overeat, or those of us who grew up on American portion sizes, this shift is transformative. Taking GLP-1s can give people more control over what they eat and take emotional eating out of the weight-loss equation.

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Nearly three in four patients (71%) feel more intentional and in control of their diet. Because GLP-1s affect appetite and taste, preparing nutritious meals and measuring portions can help users feel more in control of their eating habits instead of overwhelmed by cravings.

Another 45% feel less indifferent about their food, showing how GLP-1s can open up an emotional world to those who struggled to connect with their diets. The same number of people (45%) feel less guilt around their food after taking GLP-1s and over half (53%) report feeling less temptation. For these people, GLP-1s help them reset their relationship with food and enjoy their meals to their fullest extent.

On the flip side, 39% of users actually feel more indifferent to their food than before, but that might be a good thing. Emotional eating is often linked to patterns of binge-eating and for users with this experience, GLP-1s can help them create a more neutral relationship with their meals. 

Navigating the physical adjustment period

Because GLP-1s transform the way your body processes food, they can lead to some digestive side effects. Nausea, vomiting, and diarrhea are some of the most common side effects patients experience. For some, these symptoms fade over time. But for others, digestive issues can interfere with their daily lives. While not all patients will experience side effects to this degree, most patients will experience at least one.

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Three-quarters (75%) of patients experience digestive side effects at least monthly while taking GLP-1s. Over half (54%) experience side effects either weekly or daily. Side effects were most common among younger generations, with 64% of Zoomers and 59% of millennials experiencing daily or weekly side effects. This is nearly double the amount of Boomers who report the same, at only 34%, and Gen X, at 43%, is more aligned with Boomers. This shows that using GLP-1s may be a more intense experience for younger users.

One in five (20%) patients says their side effects have been intense enough to disrupt their sleep schedule, while 19% have woken in the middle of the night due to digestive issues. Another 19% say that acid reflux and heartburn specifically keep them up at night.

These symptoms affect people in the daylight hours, as well: 28% say fatigue from side effects impacts their work, while 22% say the side effects themselves make it more difficult to concentrate at work. Gen Z was again most intensely affected: 33% of Zoomers felt too fatigued to concentrate at work, compared to 26% of Millennials, 23% of Gen X, and 22% of Baby Boomers. Younger bodies may react more intensely to these medications, but the long-term benefits can make it worth the initial shock.  

Disclaimer: Individual results may vary. Consult your healthcare provider for medical advice. Seek immediate medical attention for severe or concerning symptoms.

Who’s talking about GLP-1s (and who’s not)

Despite the popularity of GLP-1 medications, many patients prefer to be private about their usage. Self-consciousness and social stigma can lead to people deciding not to tell friends, family, or coworkers about their GLP-1 journey. However, by keeping their medication use private, these patients also lose opportunities for support. Today’s GLP-1 users have to find a balance between staying quiet and speaking out. 

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Patients turn to friends and family first: 57% opened up about their GLP-1 usage with family members, while 52% shared their journey with close friends. Another 45% told their romantic partners and spouses about their medication use, though Gen X was most likely to turn to their spouses for support at 53%. By contrast, though, 21% say they only discussed GLP-1 usage with their healthcare provider. This was equally common among Gen Z and Baby Boomers, with 24% of each generation deciding to keep GLP-1 use between them and the doctor. Both generations seem to have the same desire for privacy. 

Among those who do share with their loved ones and colleagues, the majority (56%) feel supported by their community. A similar number (53%) feel accepted, and another 49% feel encouraged by those they discuss their medication with. Negative reactions were in the minority: 13% feel self-conscious, 10% feel judged, and 6% feel they have to justify or explain their use.

Similar to the physical side effects, younger users face more negative reactions: 37% of Gen Z and Millennials report judgment, self-consciousness, or pressure to explain, compared with 18% of Gen X and 11% of Boomers. While public perception catches up with the popularity of GLP-1 drugs, users prepare for a wide range of reactions from their friends.

How smaller appetites affect spending

With the cost of food rising faster than ever before, some are thankful to have smaller appetites. Eating smaller portions means buying less food or investing in smaller portions of better ingredients. We asked our respondents how their GLP-1 usage and appetite changes impacted their wallets.

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Nearly half (49%) of users say their grocery bills have gone down since they buy less food overall. A similar number of people (45%) say they spend less on food, because they’re buying smaller portions or choosing to splurge on indulgent foods less often. Boomers were the most likely to save money by buying less food overall, with 51% reporting savings. Nearly a third (32%) of GLP-1 users plan their meals more carefully now to manage symptoms and side effects, making grocery trips more mindful.

Not all patients ended up saving money, though. A quarter (26%) of GLP-1 users say they spend more money on food now, as they’re buying healthier and higher-quality foods. This was most common among Gen Z, with 28% saying they changed their spending to include higher-quality foods. Another 24% are spending more to accommodate their changing appetite and preferences, paying to try new and different foods. Patients adapting to their new selves spend a little more to provide for their bodies. 

However, some users also reported increased food waste and higher spending. More than one in five (22%) of users say that due to their decreased appetites, they end up not eating all of the food they buy. Another 19% say their food spending went up due to their nausea or other side effects, as they had to replace food that they could not keep down. This included 29% of Gen Z, possibly due to the relative intensity of their nausea.  

Planning for life beyond GLP-1s

For many, stopping GLP-1 use is less of a clinical milestone and more of an emotional risk calculation. While some people use GLP-1 medications as long-term health maintenance, those who take them for short-term weight loss often have mixed feelings about stopping. That tension highlights how weight-loss medications can reshape not just the body, but a person’s sense of security and control around their health.

Findings are based on self-reported survey data and are not guaranteed. Individual results may vary.

Nearly a third (31%) are afraid of gaining weight if they stop taking a GLP-1. This was felt more strongly among women than men: 37% worry about weight gain, compared to only 24% of men. This follows a societal trend in which women are stigmatized far more than men for being overweight, leading to not only judgment from peers but also from healthcare providers. 

Boomers are the most concerned about gaining weight after stopping GLP-1s, with 45% expressing worry, likely due to the higher health risks obesity poses later in life. Concern was lower among other generations, with 34% of Gen X, 29% of Gen Z, and 27% of Millennials reporting anxiety about regaining weight. With more time ahead to get in shape and lose weight, younger generations may feel less dependent on GLP-1s for permanent weight loss. 

Among users who may use GLP-1s indefinitely, though, there’s a different kind of anxiety. A minority of users (13%) say they would be relieved to stop GLP-1s if they could, and another 13% say they would feel free or liberated. Another 13% are curious about stopping, but aren’t sure how it would affect their body or mind and choose to maintain the status quo. Only 6% of respondents said they do not plan to stop taking GLP-1s, preferring their quality of life on this new medication. For many users, staying on or stopping GLP-1s isn’t about a finish line, but about managing uncertainty in a body that finally feels predictable.

More than a medication: How GLP-1s are shaping America

GLP-1s are changing more than weight. They’re changing how people live with their bodies. As these medications become part of everyday life, they are influencing confidence, routine, social behavior, and long-term planning in ways that aren’t always visible from the outside. The decision to use a GLP-1 is rarely about a single goal; it’s about finding stability in a body that has often felt unpredictable for years. 

These attitudes and decisions matter, because health outcomes don’t exist in isolation. Side effects, sleep disruption, financial shifts, and social dynamics all shape whether a treatment feels sustainable. When success is defined only by weight loss, those realities are easy to overlook, but they play a significant role in overall well-being. Taking a holistic view of GLP-1 use helps move the conversation beyond “does it work?” toward “does it work for someone’s life?”

As access and visibility continue to grow, patients and providers alike will need better frameworks for discussing trade-offs, expectations, and long-term use. A more honest view of life on GLP-1s can support better decision-making, reduce stigma, and create space for individualized definitions of health. In that sense, the real impact of these medications may lie not just in what they help people lose, but in how they help people live.

Methodology

Shed surveyed 1,000 U.S. adults who have taken GLP-1 medications (such as Ozempic, Wegovy, Mounjaro, or Zepbound®) through an online poll. 71% of respondents are currently taking a GLP-1, while 29% took one in the past. The survey measured physical side effects, emotional relationships with food, social disclosure patterns, lifestyle changes, and concerns about the future. Data was stratified to ensure representative results. Percentages reflect self-reported data and may sum to more than 100% when multiple selections were allowed.

About Shed

Shed is a digital health platform focused on helping people build sustainable, healthier relationships with their bodies through evidence-based care. By combining medical support, education, and behavioral insight, Shed helps patients navigate weight management with clarity, realism, and long-term perspective.

Disclaimer: Shed is a telehealth and communications platform and does not provide medical advice or practice medicine. Medical services and prescriptions are provided by independent, licensed providers following a clinical consultation; a prescription is not guaranteed. Compounded medications are not FDA-approved and are prepared by licensed pharmacies based on provider prescriptions. Brand-name medications referenced are FDA-approved products owned by their respective manufacturers. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly. Individual results may vary; any outcomes or data cited are not guarantees. Figures are self reported. GLP-1 medications may cause side effects. For urgent medical concerns, contact your provider or call 911. See full terms at tryshed.com/terms.

Fair use statement

You may use the information in this article for non-commercial purposes only. If you share it, provide proper attribution and a link back to Shed.